Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% ...

Fresh leaks on Google's Vertex AI platform point to an imminent launch for Gemini 3 Pro and Nano Banana 2, as the company ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

Vertex Inc (VERX) reports robust cloud revenue growth and announces a $150 million share repurchase, despite facing customer ...

Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older CF ...

Q3 2025 Earnings Call Transcript November 3, 2025 Vertex, Inc. reports earnings inline with expectations. Reported EPS is ...

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

Wall Street is reeling under extreme volatility since the beginning of 2022. Investors are highly concerned about soaring inflation. Moreover, the uncertainty regarding the pace and magnitude of an ...

Fulcrum is Vertex’s second acquisition since partnering with Wind Point in August of 2021 Based in Chicago, Wind Point Partners has about $4 billion in assets under management Wind Point invests in ...

The Phase III results impressed Guggenheim Partners analysts both in terms of efficacy and safety. If approved, atacicept would become the first APRIL/BAFF inhibitor for IgAN to make it to the market.

Vertex Capital Management has migrated its Vertex Evolution UCITS Fund to Point Nine's Circle.2 live and cloud-based service. Circle.2 provides cloud-based trade reconciliation and settlement services ...

Breakwater was established in 2019 Wind Point Partners targets investments in the consumer products, industrial products and business services sectors The firm has approximately $6 billion in assets ...